Current progress in the management of rare diseases and orphan drugs in China
スポンサーリンク
概要
- 論文の詳細を見る
Currently, the issues of how to treat rare diseases and to improve accessibility to orphan drugs are arousing more and more concerns in China. Here we describe the push and pull incentive policies for rare diseases and orphan drugs and analyze the coverage and reimbursement level of rare diseases in the current Chinese medical insurance system. Three key obstacle factors that hinder Chinese patients accessibility to timely drug treatment are summarized. Based on a comprehensive analysis, the measures of orphan drugs legislation, incentive mechanism, supply mechanism, and reimbursement mechanism are urgently expected to be established with the purpose of improving healthcare for patients with rare diseases in China.
- 特定非営利活動法人 バイオ＆ソーシャル・サイエンス推進国際研究交流会の論文
特定非営利活動法人 バイオ＆ソーシャル・サイエンス推進国際研究交流会 | 論文
- Traditional Chinese medicine and related active compounds: A review of their role on hepatitis B virus infection
- The etiologies of new cases of cerebral venous sinus thrombosis reported in the past year
- The supercritical CO2 extract from the skin of Bufo bufo gargarizans Cantor blocks hepatitis B virus antigen secretion in HepG2.2.15 cells
- HDAC6: Physiological function and its selective inhibitors for cancer treatment
- High prevalence of HIV-associated neurocognitive disorder in HIV-infected patients with a baseline CD4 count ≤ 350 cells/μL in Shanghai, China